ADMA Biologics Inc (ADMA)
Return on assets (ROA)
Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
---|---|---|---|---|---|---|
Net income | US$ in thousands | -28,239 | -65,904 | -71,648 | -75,749 | -48,279 |
Total assets | US$ in thousands | 329,182 | 348,461 | 276,253 | 207,673 | 127,091 |
ROA | -8.58% | -18.91% | -25.94% | -36.48% | -37.99% |
December 31, 2023 calculation
ROA = Net income ÷ Total assets
= $-28,239K ÷ $329,182K
= -8.58%
ADMA Biologics Inc's return on assets (ROA) has demonstrated a decreasing trend over the past five years. The ROA decreased from -37.99% in 2019 to -8.58% in 2023. This indicates that the company's ability to generate profits from its total assets has improved during this period. Despite the improvement, the company still has challenges in efficiently utilizing its assets to generate profits, as evidenced by the negative ROA figures. It is important for ADMA Biologics Inc to focus on enhancing its operational efficiency and profitability in order to increase its return on assets in the future.
Peer comparison
Dec 31, 2023
Company name
Symbol
ROA
ADMA Biologics Inc
ADMA
-8.58%
Amgen Inc
AMGN
6.91%
Bio-Techne Corp
TECH
6.22%
Biogen Inc
BIIB
4.33%
Gilead Sciences Inc
GILD
9.12%
Halozyme Therapeutics Inc
HALO
16.25%
Krystal Biotech Inc
KRYS
1.34%
Moderna Inc
MRNA
-25.58%
Neurocrine Biosciences Inc
NBIX
7.68%
Regenxbio Inc
RGNX
-45.91%
Repligen Corporation
RGEN
1.47%